Medincell’s Chief Strategy Officer to Present at Piper Sandler CNS Symposium
Event summary
- Medincell’s Chief Strategy Officer, Dr Grace Kim, will participate in the Piper Sandler CNS Symposium on August 13, 2026.
- The virtual fireside discussion with investors is scheduled for 12:30 p.m. ET.
- One-on-one meetings with Medincell can be arranged directly.
- Medincell’s Risperidone LAI (UZEDY®) received FDA approval in April 2023 and October 2025 for schizophrenia and Bipolar I Disorder, respectively.
The big picture
Medincell’s participation in the Piper Sandler CNS Symposium underscores its focus on investor engagement amid key regulatory milestones. The company’s BEPO® technology, licensed to Teva as SteadyTeq™, positions it in the competitive landscape of long-acting injectables for mental health disorders. With multiple approvals and pipeline candidates, Medincell is poised to expand its commercial footprint, but success hinges on sustained partnerships and execution.
What we're watching
- Regulatory Milestones
- Whether the FDA and EMA approvals for Olanzapine LAI will accelerate Medincell’s market penetration.
- Pipeline Progress
- The pace at which Medincell advances its investigational pipeline through clinical trials.
- Partnership Dynamics
- How Medincell’s collaboration with Teva will impact its commercial strategy and revenue growth.